Brief: Nexcella Announces Additional Positive NXC-201 Clinical Data
06/01/2023 13:15
Jan 6 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA SUBSIDIARY NEXCELLA, INC. ANNOUNCES
ADDITIONAL
POSITIVE NXC-201 CLINICAL DATA DEMONSTRATING 100% COMPLETE
RESPONSES IN RELAPSED/REFRACTORY AL AMYLOIDOSIS PATIENTS,
DURATION OF RESPONSE NOT YET REACHED
Source text for Eikon: ID:nGNE4twTvj
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary